AstraZeneca, breast cancer and US FDA
FDA Approves New ADC for HR+, HER2- Breast Cancer
The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan for the treatment of certain patients with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer.
AstraZeneca’s Datroway approved in U.S. for HER2-negative breast cancer patients
DXd, has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.
ZME Science on MSN3h
New AI Blood Test with Lasers Finds Breast Cancer in Its Earliest StageIf breast cancer is detected at stage I, there is a 99% chance the patient will survive for the next five years at least.
It’s a sobering statistic: 1 in 8 women in the United States will be diagnosed with breast cancer during her lifetime.1 ...
BISMARCK, N.D. (Valley News Live) - A bill proposed in the North Dakota House aims to provide health coverage with no cost-sharing for additional breast screenings for individuals at greater risk for ...
The increase in breast cancer rates among younger patients is occurring as the incidence of other early-onset cancers — ...
Danielle Fishel is sharing an update about her health, saying she has completed “active cancer treatment” following her ...
If you have breast cancer, you will have changes in your breast. These may be lumps or changes in the size or color of your breast, or changes in the appearance of your nipples. Breast cancer ...
As cancer treatment costs have increased, identifying and treating early-stage cancer sooner reduces expenses and improves ...
Questions about sex and intimacy often go unanswered for people with cancer. It's a glaring problem, especially for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback